On Friday, shares of biotechnology giant Biogen (BIIB) closed sharply higher, surging 8.54%, making it one of the market’s standout performers for the day. This strong rally was primarily driven by the company’s release of its final 2025 full-year financial results, which significantly exceeded the average expectations of market analysts in terms of both realized profits and future earnings guidance, successfully boosting investor confidence.
Specifically, Biogen’s total revenue for the fourth quarter was $2.28 billion, a 7% decline from the same period last year. Non-GAAP net profit saw a more pronounced drop, falling from over $502 million in the same period last year to $294 million (or $1.99 per share). Despite the year-over-year decline in key financial metrics, its performance still outperformed market consensus: analysts had previously expected quarterly revenue of approximately $2.21 billion and Non-GAAP earnings per share of just $1.61.
As the company’s primary revenue source, product revenue fell 9% year-over-year to below $1.67 billion. Within this, the largest drug category—multiple sclerosis (MS) treatments—experienced a double-digit decline in sales, down 14% year-over-year to $917 million, due to ongoing competition from generics and biosimilars.
In addition to exceeding expectations for past performance, Biogen’s full-year guidance for 2026 also paints a positive picture. The company stated that this guidance “reflects sustained business momentum and financial discipline.” Biogen expects total revenue in 2026 to decline by a mid-single-digit percentage compared to 2025, but adjusted earnings per share are projected to be between $15.25 and $16.25. This earnings guidance range is significantly higher than the analyst consensus of $14.92.
Analysts believe that Biogen’s substantial outperformance in both realized profits and future earnings expectations clearly indicates that the company is successfully reducing its historical reliance on its traditional multiple sclerosis product portfolio. Sales of its “new Biogen” drug series grew by 6%, and the company maintains a strong research and development pipeline, which is expected to further diversify its product offerings. Market participants were evidently encouraged by this better-than-expected financial report and outlook, leading to active buying that ultimately drove the stock to a nearly 9% gain on Friday.
